Abstract: The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.

Abstract: The invention relates to the use of compounds of the formula (I), in which R1, R2, m and n have the meanings indicated in the Claims, and/or physiologically acceptable salts, tautomers, stereoisomers and/or solvates thereof, including mixtures thereof in all ratios, for the inhibition of tyrosinase and for lightening the skin. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of pigment disorders of the skin. The invention furthermore relates to preparations comprising the compounds of the formula (I) in combination with at least one further active compound and to a process for the preparation of the preparations by mixing the compounds of the formula (I) with a vehicle which is physiologically acceptable for topical applications.

Abstract: The invention relates to the use of specific disaccharides and derivatives thereof as self-tanning substance or as tanning enhancer for dihydroxyacetone or for a mixture of self-tanning substances comprising dihydroxyacetone. The invention furthermore relates to the use thereof for the modulation of the hue which is achieved on tanning with dihydroxyacetone or by the mixture or preparation comprising dihydroxyacetone. The invention furthermore relates to the use thereof in a mixture or preparation comprising at least dihydroxyacetone as self-tanning substance as contrast-reduction agent. The use of such compounds facilitates a significantly improved colouring result of the skin.

Abstract: The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.

Abstract: The present invention relates to the use of specific aldehydes or ketones of the formula I as photostabiliser for at least one compound to be stabilised. The invention furthermore relates to a method for the photostabilisation of a second compound by a compound of the formula I and to compositions comprising at least one compound of the formula I of this type.

Abstract: The invention relates to the use of at least one specific triazine or melamine and/or salt thereof as accelerator for a photoinduced reaction of 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)-propan-1-one, 1-(4-tert-butylphenyl)-3-hydroxy-3-(4-methoxyphenyl)-propan-1-one or a mixture of these compounds to give avobenzone. The invention furthermore relates to a composition comprising at least one specific triazine or melamine and to a method for the stabilisation of the UV absorption capacity of a composition by means of a mixture of at least one specific triazine or melamine together with 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)propan-1-one, 1-(4-tert-butylphenyl)-3-hydroxy-3-(4-methoxyphenyl)propan-1-one or a mixture of these compounds, particularly preferably together with 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)propan-1-one.

Abstract: The present invention relates to styrene-based copolymers having recurring units which contain substituted anthracenes in the side chain, to blends comprising these polymers according to the invention, and to the use of these polymers and blends in electronic devices. The invention furthermore relates to electronic devices which contain these polymers or blends.

Abstract: The present invention relates to a method for producing a brush head for a toothbrush head in which the bristle tufts that are already fixed to a bristle support of the brush head are cut at the free ends thereof such that a desired tuft end contour is generated. According to the invention, at least one bristle tuft is bent away at least in parts and held in a bent-away position while the tuft end contour of this at least one and/or of another bristle tuft is cut.

Abstract: The present invention relates to cross-linkable and cross-linked polymers and to a method for the production thereof. The invention further relates to the use of said polymers in electronic devices and to the corresponding electronic devices themselves.

Abstract: The present invention relates to a ligand which specifically binds to the human tumor necrosis factor type 1 receptor (huTNFR1), the ligand comprising one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in human beings and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention further relates to a nucleic acid encoding said ligand and to a pharmaceutical composition for the treatment of disorders connected to huTNFR1.

Abstract: The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.

Abstract: The invention relates to polypeptides comprising, as constituent A, at least three monomers of a member of the TNF ligand family and, as constituent B, at least two peptide linkers that link the monomers of the member of the TNF ligand family to one another. The invention also relates to the use of these polypeptides for treating diseases and for producing a medicament or a vaccine. The invention also relates to methods for producing and isolating these polypeptides, to nucleic acids that code for these polypeptides, to vectors containing these nucleic acids, to host cells transfected with these vectors, and to pharmaceutical compositions containing these inventive objects. Finally, the invention relates to methods for the extracorporeal manipulation, depletion and/or removal of components contained in body fluids, e.g. by means of apheresis.

Abstract: The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.

Abstract: The present invention relates to a polypeptide having preferably antitumoral and/or immunomodulating cytokine properties, which can be activated by processing in vivo comprising a central region with specific biological activity. At its C-terminus said region has a region with a processing unit and an inhibitor domain, while at the N-terminus of the central region, there is a region that selectively recognizes a macromolecule on a cell surface or a component of the extracellular matrix.

Abstract: A monoclonal antibody, or fragments thereof, against human TNF receptor protein which antibody neutralizes the known actions of TNF.alpha. and/or TNF.beta. is disclosed. The antibody may be chimeric or humanized. Furthermore, the present invention provides a process for obtaining the above monoclonal antibody, as well as a pharmaceutical composition containing the above monoclonal antibody and/or the above protein with antibody properties.